Study of Belantamab Mafodotin with Carfilzomib, Pomalidomide, and Dexamethasone for Relapsed Multiple Myeloma
This study is looking into a combination of four drugs: belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone. Doctors want to see if this combination is safe and effective for people with multiple myeloma (a type of blood cancer) that has returned or worsened after previous treatments, including CAR T-cell therapy. The study aims to enroll 83 participants. For those who haven't had CAR T-cell therapy, success means a very good partial response to treatment. For those who have had CAR T-cell therapy, success means an overall response to treatment. The study's current status is unclear.
- Study design
- This interventional study plans to enroll 83 participants. It is testing a specific combination of four drugs.
- What's involved
- Participation in this research will last about 6 to 24 months, but it may be shorter or longer depending on your response to treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main goals of the study are measured between 6 and 24 months, suggesting follow-up during this period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Benjamin Derman, MD · PRINCIPAL_INVESTIGATOR · University of Chicago
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Rate of Very Good Partial Response (No Prior CAR T-Cell Therapy Cohort)6-24 months
No prior CAR T-cell therapy cohort: Rate of very good partial response (VGPR) or better after 6 cycles according to the 2016 International Myeloma Working Group (IMWG) Response Criteria by Independent Review Committee (IRC).
- Rate of Overall Response (Prior CAR T-Cell Therapy Cohort)6-24 months
Prior CAR T-cell therapy cohort: Rate of overall response (ORR) as determined by investigator assessment.